Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
← catalyst calendarNCT07146022 · readout ≤ 314 d
Sponsored by Veradermics, Inc. (industry) · MANE — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
552estimated
Sites
71
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-25 | actual | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Androgenetic Alopecia (AGA)
- Androgenetic Alopecia
- AGA
- Female Androgenetic Alopecia
- Hair Loss
Interventions
- Drug: VDPHL01 QD
- Drug: Placebo
- Drug: VDPHL01 BID
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFChanges in non-vellus Target Area Hair Counts (TAHC)
measured Month 6
Subjects Evaluation of Treatment Benefit
measured Month 6
Permalink · MANE's whole pipeline · Catalyst calendar · Every registered study · What changed